DiaMedica Therapeutics (DMAC) Peer Comparison

$6.35

$-0.04 (-0.63%)

As on 31-Aug-2026 16:01EDT

Market cap

$345 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

9.5

Div. Yield

0 %

Edit

	DiaMedica Therapeutics (DMAC)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	Fennec Pharmaceuticals (FENC)
Market cap ($ Mln)	345	5,809	2,167	3,678	430
Revenue ($ Mln)	0	--	312	66	59
Net Profit ($ Mln)	-37.54	-409.20	314.11	-164.66	-3.25
Net Margin (%)	134,079.79	--	100.84	-248.83	-5.49
RoE (%)	-79.49	-44.86	52.52	-17.68	-8.35
Price to Earnings	--	--	7.14	--	--
Price-To-Book	9.49	4.83	3.57	4.48	9.71

Cashflow
Ratios

Cashflow ($ Mln)

	DiaMedica Therapeutics (DMAC)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	Fennec Pharmaceuticals (FENC)
Cash From Operating Activities	-29.06	-279.12	135.66	-131.30	-12.47
Cash Flow from Investing Activities	-2.19	218.00	-32.77	87.75	--
Cash from Financing Activities	43.88	117.11	-106.11	14.08	22.63
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	DiaMedica Therapeutics (DMAC)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	Fennec Pharmaceuticals (FENC)
ROCE (%)	-67.28	-51.11	51.61	-13.12	-40.15
ROE (%)	-79.49	-44.86	52.52	-17.68	-8.35
ROA (%)	-60.11	-27.75	42.65	-11.64	-3.23
EBIT Margin (%)	133,972.64	--	54.20	-304.58	-4.19
Net Margin (%)	134,079.79	-4,612.13	100.84	-248.83	-5.49
Cash Profit Margin (%)	3.35	--	0.00	0.00	0.00

Growth Ratios

	DiaMedica Therapeutics (DMAC)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	Fennec Pharmaceuticals (FENC)
Revenue Growth (%)	-100.20	--	19.76	101.28	77.83
EBIT Growth (%)	-26.93	3.41	151.91	23.59	70.81
Net Profit Growth (%)	-26.91	-47.07	418.03	0.61	72.99
EPS Growth (%)	-6.40	-34.29	434.98	2.53	73.38
Book Value Growth (%)	12.47	55.33	96.66	-13.08	531.86

Valuation Ratios

	DiaMedica Therapeutics (DMAC)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	Fennec Pharmaceuticals (FENC)
Price / Earnings	-11.41	-10.27	7.70	-6.98	-24.64
Price / Book Value	6.66	6.11	3.81	1.06	6.85
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-9.61	-8.80	14.79	-4.24	-27.28
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	DiaMedica Therapeutics (DMAC)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	Fennec Pharmaceuticals (FENC)
Debt to Equity	0.00	0.00	0.00	0.00	0.00
Short term debt to equity ratio	0.00	0.00	0.03	0.01	0.00
Current Ratio	6.72	21.02	5.42	12.77	5.85
Quick Ratio	6.72	21.02	4.97	12.63	5.66
Interest Coverage	--	--	17.75	-11.19	-2.43

Operating Efficiency Ratios

	DiaMedica Therapeutics (DMAC)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	Fennec Pharmaceuticals (FENC)
Debtors to sales (%)	0.00	18.28	13.21	144.21	39.29
Asset Turnover	0.00	0.00	0.42	0.05	0.59
Receivable days	--	69.15	50.32	596.85	147.53
Inventory Days	--	--	474.76	40.15	127.22
Payable days	--	643.10	47.52	377.52	381.73
Cash Conversion Cycle	--	--	477.57	259.48	-106.97

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly